DNMT1: A Key Drug Target in Triple-Negative Breast Cancer
Publication date: Available online 24 May 2020Source: Seminars in Cancer BiologyAuthor(s): Keng Wong Kah
Mice that experienced heart attacks underwent a large-scale shift in their immune systems that allowed cancer to flourish, perhaps explaining the observation in patients.
Condition: Primary Breast Cancer Intervention: Device: Tumark® Vision clip Sponsor: Kliniken Essen-Mitte Recruiting
Condition: Breast Cancer Intervention: Sponsor: University of Aberdeen Recruiting
Conditions: Breast Cancer; Surgery Intervention: Other: Coaching sessions Sponsor: Institut Curie Not yet recruiting
Condition: HER2 Positive Breast Cancer Intervention: Drug: AIP-303 Sponsors: Advanced Imaging Projects, LLC; All India Institute of Medical Sciences, New Delhi Not yet recruiting
A. K. GATTA, R. CHANDRASHEKHAR, N. UDUPA, M. S. REDDY, S. MUTALIK AND V. R. JOSYULA*
This study demonstrated that the expression level of ankyrin repeat domain 22 (ANKRD22) in human breast cancer tissues was significantly higher than that in normal breast tissues. ANKRD22 knockdown inhibited the proliferation, invasion, and epithelial-mesenchymal transition (EMT) of breast cancer cells. Further research indicated that ANKRD22 regulated the expression of nucleolar and spindle-associated protein 1 (NuSAP1) and then the activation of Wnt/β-catenin signaling pathway. Moreover, overexpression of NuSAP1 reversed the inhibitory effects of ANKRD22 knockdown on the proliferation, invasion, and EMT of breast ca...
Conclusion: Patient age has a significant influence if elderly patients with axillary disease receive radiotherapy. Further investigation and validation are needed to understand why chronological age rather than biological age influences treatment modalities.Breast Care
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...